Brief: Ascelia Pharma Q4 EPS Loss Narrows To Sek 0.13
05/02/2026 06:41
Feb 5 (Reuters) - Ascelia Pharma AB ACELP.ST: Q4 EPS SEK -0.13 Q4 CASH FLOW FROM OPERATIONS SEK -21.7 MILLION Q4 EBIT SEK -15.8 MILLION WE HAVE A CASH RUNWAY INTO Q4 2026, WELL BEYOND EXPECTED FDA APPROVAL DATE OF ORVIGLANCE Source text: ID:nMFN9m34lD Further company coverage: ACELP.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))